| Drug Name |
Ponatinib hydrochloride |
| Drug ID |
BADD_D01800 |
| Description |
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. |
| Indications and Usage |
Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EA05 |
| DrugBank ID |
DB08901
|
| KEGG ID |
D09951
|
| MeSH ID |
C545373
|
| PubChem ID |
46908927
|
| TTD Drug ID |
D0H0EQ
|
| NDC Product Code |
42973-242; 63020-535; 63020-536; 63020-533; 63020-534; 48957-0070; 54893-0124 |
| UNII |
96R6PU3D8J
|
| Synonyms |
ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig |
